Compared with women without bladder problems, women who have interstitial cystitis are more likely to have irritable bowel syndrome and depression, researchers report. They hypothesize that bladder ...
A phase 2a clinical trial of Urovant’s vibegron in irritable bowel syndrome (IBS) patients has missed its primary endpoint. The setback dents Urovant’s prospects in one indication but still leaves it ...
Quality of Life Research, Vol. 6, No. 7/8, The Improvement of Quality of Life: A Purpose of Health Care: Abstracts: 4th Annual Conference of the International Society for Quality of Life Research (Oct ...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial ...
HealthDay on MSN
Overactive Bladder Prevalent Among Women With Fibromyalgia
Overactive bladder (OAB) is prevalent among women with fibromyalgia (FM) and is associated with higher symptom severity and comorbidity, according to a study pu ...
Overactive bladder (OAB) is prevalent among women with fibromyalgia (FM) and is associated with higher symptom severity and ...
Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically significant Vibegron was generally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback